Autism Spectrum Disorder (ASD) is a common neurodevelopmental disorder affecting approximately 1% of children. ASD is defined by core symptoms in two domains: negative symptoms of impairment in social and communication function, and positive symptoms of restricted and repetitive behaviors. Available treatments are inadequate for treating both core symptoms and associated conditions. Twin studies indicate that ASD susceptibility has a large heritable component. Genetic studies have identified promising leads, with converging insights emerging from single-gene disorders that bear ASD features, with particular interest in mammalian target of rapamycin (mTOR)-linked synaptic plasticity mechanisms. Mouse models of these disorders are revealing not only opportunities to model behavioral perturbations across species, but also evidence of postnatal rescue of brain and behavioral phenotypes. An intense search for ASD biomarkers has consistently pointed to elevated platelet serotonin (5-HT) levels and a surge in brain growth in the first 2 years of life. Following a review of the diversity of ASD phenotypes and its genetic origins and biomarkers, we discuss opportunities for translation of these findings into novel ASD treatments, focusing on mTor-and 5-HT-signaling pathways, and their possible intersection. Paralleling the progress made in understanding the root causes of rare genetic syndromes that affect cognitive development, we anticipate progress in models systems using bona fide ASD-associated molecular changes that have the potential to accelerate the development of ASD diagnostics and therapeutics.
children (Autism and Developmental Disabilities Monitoring Network Surveillance Year 2002 Principal Investigators; Centers for Disease Control and Prevention, 2007) . It is not clear how much of this increase is due to broadened criteria, improved diagnostic tools, or other unknown factors. Reflecting the difficulty in finding clear boundaries between the PDDs, the upcoming revision of the DSM (DSM-V at http://DSM5.org) will likely include only one diagnosis, Autism Spectrum Disorder (ASD), instead of separating out Asperger's Disorder and Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS). This spectrum diagnosis reflects the broad heterogeneity observed across individuals with social communication dysfunction and repetitive behavior.
Each of the three current symptom domains can be quite variable from individual to individual sharing a PDD diagnosis. For example, Lorna Wing and others have noted disparate patterns of social motivation, including children who are socially uninterested or 'aloof,' but also children who are socially motivated but qualitatively impaired in their interactions, whom Wing describes as 'active but odd' (Waterhouse et al, 1996) . Impairment also varies widely in the communication domain, with a substantial number of children who never achieve verbal speech but others whose speech may be most notable for odd prosody or idiosyncratic phrasing. Finally, the repetitive behavior domain is quite diverse, including intense restricted interests, simple repetitive motor mannerisms, inflexible rituals or routines, or preoccupation with parts of objects, with each child only required to show two of these positive symptoms (American Psychiatric Association, 2000; Richler et al, 2007 Richler et al, , 2010 . Recent work in sibling pairs affected with autism suggests that individual symptom domains or sub-domains may be separately inherited, particularly in the case of repetitive behavior (Georgiades et al, 2007; Lam et al, 2008; Smith et al, 2009; Tadevosyan-Leyfer et al, 2003) .
PERSPECTIVE
The planned incorporation of a 'spectrum' term in the description of 'ASD' in the DSM-V reflects an extremely complex and heterogeneous syndrome as notable for its variability as for its core features (Figure 1) . Surely, the broadening of phenotype is not unique to ASD, as we now recognize that many brain disorders represent clusters of similar but not identical symptoms. No two individuals present with exactly the same features, attesting to the complexity of our genetic heritage, environmental exposure, and brain development and plasticity. With respect to the complexity of autism, we will argue for an integrative approach that seeks to follow systems that are implicated across multiple research modalities. In the space provided, . ASD symptoms, comorbidities, and biomarkers. The core symptoms of ASD are represented in the center and represent the common features required to receive a diagnosis. All three social communication/social interaction symptoms are required to receive a diagnosis in the DSM-V draft criteria. This domain represents the 'negative symptoms' of ASD, that is, absence of appropriate social communication. Two of the four restricted/ repetitive behavior symptoms are required to receive a diagnosis in the DSM-V draft criteria. This domain represents the 'positive symptoms' of ASD, that is, the presence of unusual restricted, repetitive, or sensory behaviors. Around the periphery of the figure are symptoms or biomarkers that are not required for an ASD diagnosis but are more common in ASD than in the general populations. Quite a number of comorbid disorders or symptoms are seen in a substantial minority or even a majority of individuals with ASD, spanning cognitive, behavioral/psychiatric, and medical domains. As might be expected from the range of comorbid symptoms, biomarkers and genetic findings also reveal significant heterogeneity across individuals with ASD.
we cannot enumerate all findings across the relevant research modalities. Instead, after a review of comorbidities that illustrate the complexities of the medical problems of ASD and the limited treatments available, we discuss the genetic and environmental factors reported to impact ASD risk and available ASD biomarkers, particularly those that could drive the search for potential therapeutics. Lastly, we discuss findings within networks that converge on the mammalian target of rapamycin (mTor) pathway and the serotonin (5-hydroxytryptamine, 5-HT) transporter (SERT) as two specific examples of how further preclinical research may provide new opportunities for improved diagnosis and treatment. We refer the reader to other networks and paradigms gaining traction (Bill and Geschwind, 2009; Ehninger et al, 2008b; Levitt and Campbell, 2009; Ramocki and Zoghbi, 2008; Sudhof, 2008) , as we expect that multiple avenues will need to be pursued given the heterogeneity of ASD.
COMORBIDITY IN ASD
Children with ASD frequently show comorbid symptoms that are not part of the diagnostic criteria. These include both general and specific cognitive impairment . Approximately 1/3 of children with ASD (although with a decreasing ratio as diagnosis increases) show intellectual disability, or IQ two standard deviations below the mean (Chakrabarti and Fombonne, 2005) . Specific cognitive deficits have been described in groups of children with ASD, prominently including impairment in executive function (Hill, 2004) . Others have posited 'weak central coherence' as a central deficit in ASD, with patients failing to see or understand group relationships (Happe and Frith, 2006) . Changes in sensory function are common in ASD. Some children with ASD show marked hypersensitivity to specific stimuli, whereas others show apparent insensitivity to the environment, including painful stimuli Boyd et al, 2010) . A few studies show empirical support for altered sensory processing; although more research is needed in this area (Cascio et al, 2008; Coskun et al, 2009; Kwakye et al, 2011; Tommerdahl et al, 2007) .
Epilepsy is common in ASD, with up to 25% of children affected. The emergence of epilepsy shows two peaks, with some children developing seizures during the first few years of life and a second group developing seizures during adolescence. Beyond those children who have seizures, up to 50% of children with ASD have an abnormal electroencephalogram (Chez et al, 2006; Hrdlicka et al, 2004; Kim et al, 2006) . This observation has led some to hypothesize that there is an imbalance favoring excitatory over inhibitory neurotransmission in ASD (Rubenstein and Merzenich, 2003) .
Gastrointestinal symptoms have also received considerable attention in ASD (Buie et al, 2010; Erickson et al, 2005) . Despite considerable anecdotal evidence of gastrointestinal dysfunction, available research primarily points to excess constipation and accompanying encopresis (leakage of stool) in ASD (Ibrahim et al, 2009; Wang et al, 2011) .
A wide variety of behavioral symptoms are also more commonly seen in ASD than in the general population. Hyperactivity and impulsivity are particularly common and frequently lead to impairment (Simonoff et al, 2008; Volkmar et al, 1999) . Aggression and self-injury are also common, particularly in individuals with comorbid intellectual disability (Parikh et al, 2008; Volkmar et al, 1999 ). Anxiety appears to be more common (Mattila et al, 2010; Simonoff et al, 2008) ; although current measures have difficulty capturing anxiety symptoms in the ASD population . Obsessive-compulsive symptoms are also frequent, but these are difficult to separate from the wide range of repetitive behaviors that can be seen in ASD (Jacob et al, 2009; Leyfer et al, 2006) .
Overall, the pattern of comorbid symptoms in ASD is broad and matches the heterogeneity in core symptoms. Competing approaches can be taken to the patterns of core and comorbid symptoms. We could, as a field, approach each set of symptoms separately, making each diagnosis that is justified by symptoms (ie, describing a child as having ASD with comorbid epilepsy, constipation-encopresis, sensory aversion, and hyperactivity). Alternatively, we could hypothesize that all of the symptoms most likely reflect a single underlying etiology. Neither approach has clearly won out at this point, but comorbid physical and behavioral symptoms are likely to prove important in separating different causes of ASD.
CURRENT TREATMENT OF ASD
Unfortunately, available treatments for ASDs are inadequate Warren et al, 2011) . Many children receive treatments based upon applied behavior analysis (ABA), an approach that incrementally reinforces components of core social and communication skills while working to minimize interference from repetitive behavior. Early intensive behavioral interventions that incorporate 30 + hours per week of therapy using ABA principles may improve symptoms for some children but do not often lead to complete remission of symptoms (Dawson et al, 2010; Smith et al, 2000) . Other, less intensive, behavioral interventions targeting social skills have less data to support their use (Beaumont and Sofronoff, 2008; Warren et al, 2011) . Some treatment strategies seek to work around deficits by adapting communication systems or educational settings to individual needs (Panerai et al, 2009; Yoder and Lieberman, 2010) . Overall, these behavioral interventions are the mainstay of current treatment and do lead to improved function in some children, but they do not cure ASD symptoms in most children .
Current medications primarily show benefit for comorbid symptoms in ASD, rather than leading to improvement in core symptom domains . Some treatments, such as stimulant medications, may be effective in reducing hyperactivity and impulsivity symptoms (Network, 2005) . Other treatments, including the atypical antipsychotics risperidone and aripripazole, can effectively target comorbid irritability, agitation, and aggression (Marcus et al, 2009; McCracken et al, 2002) . Some evidence shows that atypical antipsychotics may also benefit repetitive behavior symptoms . The 5-HT reuptake inhibitors (SRIs) may also provide benefit for distressing repetitive behaviors in some people with ASD, but the data regarding population efficacy are inconsistent (Hollander et al, 2005; King et al, 2009a; McDougle et al, 1996) . To date, none of these treatments are based upon a specific understanding of the causes of ASD.
ASD SUSCEPTIBILITY FACTORS

Genetic Factors
The path to improved diagnosis and treatment of ASD requires a more sophisticated understanding of biological and environmental susceptibilities. Twin and family studies have demonstrated that heritability has a large role in autism. Beginning with work by Susan Folstein and Michael Rutter in the late 1970s, higher ASD concordance rates have been seen in monozygotic vs dizygotic twins, supporting a heritability of up to 90% (Bailey et al, 1995; Folstein and Rutter, 1977) . More recent twin studies have calculated a lower contribution of heritability Rosenberg et al, 2009) , perhaps reflecting changes in diagnostic criteria and population base rate, although heritability estimates remain as high or higher than any other behaviorally defined disorder.
Family studies also support a significant contribution of heritability to autism (Bolton et al, 1994) . Again, as diagnosis rates have increased in the general population, recurrence rates within families have increased as well, with estimates ranging from 3 to 11% in large samples (Bolton et al, 1994; Constantino et al, 2010b; Jorde et al, 1991; Ritvo et al, 1989) . Some studies find a much higher rate of subsequent children with ASD in families with two or more affected children, approaching 50% affected (Zhao et al, 2007) . The different patterns of recurrence risk suggest that there are multiple different patterns of inheritance contained within the population of ASD. These patterns may favor different genetic approaches in different subsets of ASD.
Several comprehensive reviews of molecular genetic findings in ASD have been published recently (Bill and Geschwind, 2009; Bourgeron, 2009; Levitt and Campbell, 2009; State, 2011; Weiss, 2009 ). We will therefore not detail the overall genetic findings in ASD but instead will focus on mTor and 5-HT networks where the biological contexts for therapeutic development are most highly developed. In Table 1 , we summarize other findings, including the identification of rare copy-number variants (CNVs) and single-gene variants that represent highly penetrant susceptibility factors, establishing, essentially, new genetic syndromes. Interestingly, some of these findings reveal ASD risk associated with both increased and decreased gene dosage. As might be expected from a gene-to-phenotype approach, the impact of a number of these susceptibility variants does not appear to respect the diagnostic boundaries of ASD and includes risk of intellectual disability, ADHD, or schizophrenia. As tabulated, a number of common polymorphisms have also been associated with ASD; although findings in this area have been slower to emerge.
In addition to specific genetic risk factors, an XY karyotype confers an increased risk of ASD, with rates at least four times higher in males than females (Fombonne, 2003) . This ratio may be further accentuated in children with higher IQ. Reciprocally, the male-to-female ratio appears lower for children with greater degrees of 
Associations with common polymorphisms
Maternal duplication of chromosome 15q11-q13 (Christian et al, 2008; Cook et al, 1997) Deletions or duplications of chromosome 16p11 Weiss et al, 2008) NLGN4X (Jamain et al, 2003) NLGN3 (Jamain et al, 2003) SHANK3 (Durand et al, 2007) SHANK2 (Berkel et al, 2010) NRXN1 Glessner et al, 2009; Kim et al, 2008; WisniowieckaKowalnik et al, 2010) PTCHD1 (Noor et al, 2010) IL1RAPL1 (Piton et al, 2008) SYNGAP1 (Hamdan et al, 2011 (Hamdan et al, , 2009 Pinto et al, 2010) SLC6A4 (Sutcliffe et al, 2005) SEMA5A ) CDH9/CDH10 ) MET (Campbell et al, , 2006 CNTNAP2 (Alarcon et al, 2008; Arking et al, 2008; Bakkaloglu et al, 2008) EN2 (Benayed et al, 2005; Brune et al, 2008; Gharani et al, 2004) intellectual disability. Various hypotheses have been raised regarding the increased risk in males. In the general population, average social communication function is lower in males in comparison with females (Constantino and Todd, 2003; Skuse et al, 2005) . Simon Baron-Cohen and coworkers have hypothesized that fetal testosterone exposure may influence social development, with some support from direct and indirect measures of fetal testosterone (BaronCohen, 2010). Skuse et al (1997) explored an alternative hypothesis in Turner Syndrome, where girls have a single X chromosome. Girls who received their single X chromosome from their mothers, as is true for all boys, had significantly worse social function than girls who received their X chromosome from their fathers, suggesting that genetic imprinting effects may account for part of the difference in social function. As tabulated, a few genes on the X chromosome have also been examined for a potential role in ASD. Further analysis of sex-specific risk factors could yield distinct treatments for male and female subjects with ASD, as has been suggested recently for PTSD (Kingwood, 2011; Ressler et al, 2011) .
Parental and Prenatal Factors
Parental and pregnancy factors appear to affect the risk of ASD. Increasing paternal or maternal age increases the risk of ASD, which may relate to a role for de novo genetic variation, including either mutations or CNVs (Durkin et al, 2008; Hultman et al, 2010; King et al, 2009b) . Increased loading of pregnancy complications has been reported in children with ASD in comparison with controls; although to date no single complication has been clearly associated with ASD (Gardener et al, 2009) . Very low birth-weight or extreme preterm birth also increases the risk of ASD. Evidence suggests that these children may have a different pattern of comorbidities, including intellectual or motor disability, in comparison with the general population of children with ASD (Buchmayer et al, 2009; Limperopoulos et al, 2008; Schendel and Bhasin, 2008; Schieve et al, 2010) . One recent study reported an increased risk of ASD following a short inter-pregnancy interval, suggesting a potential role for maternal nutritional status or other gestational factors (Cheslack-Postava et al, 2011) . A couple of rare environmental exposures during pregnancy also increase the risk of ASD (Chess, 1971) . Rubella exposure during the first trimester clearly increases the risk of ASD; although congenital rubella syndrome also includes sensorineural deafness, eye abnormalities, intellectual disability, and cardiac malformations (Duszak, 2009 ). First-trimester exposure to thalidomide also increases risk; although this is also associated with limb, eye, and cardiac malformations (Stromland et al, 1994) . Likewise, in utero exposure to valproic acid appears to increase risk; although this is also associated with a broader syndrome including neural tube defects (Williams et al, 2001) . One recent study reported an increased risk of ASD following prenatal exposure to SRI medications (fluoxetine, sertraline, etc.), especially during the first trimester (Croen et al, 2011) . Further work will be necessary to understand whether this is related to the drugs themselves, or to target symptoms or conditions that are more common in mothers of children with ASD. As a group, these prenatal risk factors are rare causes of ASD, but they suggest a window of vulnerability to environmental agents that increase ASD risk in the first trimester of pregnancy. Additionally, these causes provide opportunities to establish preclinical models whose investigation may uncover key lessons for idiopathic ASD. In this regard, rodent models of in utero viral or valproic acid exposure have been studied and are reviewed elsewhere (Patterson, 2011) .
BIOMARKERS IN ASD
There is a long tradition of biomarker research in ASD. Biomarkers may point toward ASD susceptibility factors in different ways. In theory, a biomarker could contribute directly to susceptibility, but a biomarker also may represent an endophenotype, or a heritable trait resulting from an underlying factor that is the prime contributor to ASD susceptibility (Gottesman and Gould, 2003) . Finally, a biomarker may be a secondary result of ASD itself or of ASD treatment. Deciding among these possibilities has therapeutic relevance in narrowing down potential targets and/or using the particular measure as a diagnostic or treatment aid.
The first biomarker described in ASD was elevated wholeblood 5-HT, or hyper-serotonemia, first identified 50 years ago (Schain and Freedman, 1961) , and unique to autism among developmental disorders (Hanley et al, 1977; Mulder et al, 2004) . Remarkably, gut enterochromaffin cells that synthesize peripheral 5-HT have never been directly assessed in ASD. In the blood, 5-HT is contained almost exclusively in platelets, which acquire 5-HT through the SERT as they pass through the gut circulation. Not surprisingly, whole-blood 5-HT levels are correlated with SERT-mediated 5-HT uptake (Cook et al, 1993; Cross et al, 2008) . Additional abnormalities have been found in the platelet in ASD, including decreased radioligand binding to the 5-HT 2A receptor (Cook et al, 1993; McBride et al, 1989) . Importantly, whole-blood 5-HT levels have been shown to be highly heritable, more heritable than ASD itself (Abney et al, 2001) . Postnatal platelet 5-HT is unlikely to directly affect brain function, given its lack of penetration of the blood-brain barrier, but the protein networks regulating peripheral 5-HT homeostasis are largely conserved in the brain. Indeed, the SERT gene (SLC6A4) and the 5-HT receptor 5-HT 2A gene (HTR2A) encode the same protein in the platelets and brain (Cook et al, 1994; Lesch et al, 1993) . Abnormalities in brain 5-HT systems have also been described in ASD, including an altered developmental trajectory of 5-HT turnover (Chugani et al, 1999) and decreased radioligand binding to both 5-HT 2A (Goldberg et al, 2009; Murphy et al, 2006) and SERT (Nakamura et al, 2010) .
The known role of the 5-HT system in brain development raises the possibility that changes in 5-HT homeostasis during development result in altered neuronal migration or neurite outgrowth. As one example, 5-HT modulates thalamocortical axon projections to the sensory cortex, with excessive extracellular 5-HT leading to disruption of the somatosensory map in rodents (Bonnin et al, 2007; Salichon et al, 2001) . Recently, Bonnin and colleagues discovered that the placenta synthesizes and releases 5-HT during embryonic brain development at a point before serotonergic raphe axons innervate the forebrain. Moreover, placental release of 5-HT appears to account for the forebrain 5-HT levels at this time, independent of the brain's synthetic capacity (Bonnin et al, 2011) . These studies add another dimension to the complex role of 5-HT in brain development. Interestingly, the placenta is also a site of high-level expression of SERT proteins (Prasad et al, 1996) . Indeed, human SERT was first cloned from placenta (Ramamoorthy et al, 1993) , presaging these most recent studies. The recent finding that prenatal exposure to SRIs may increase ASD risk could therefore point to their activity in the maternal circulation, the placenta, or the developing fetal brain (Croen et al, 2011) .
Developmental studies of both head circumference and MRI-derived whole-brain size have identified an abnormal rate of brain growth over the first few years in ASD. Using a combination of cross-sectional and longitudinal data, Eric Courchesne and others have identified a surge in brain growth in the first 2 years of life in children with ASD (Courchesne et al, 2003 (Courchesne et al, , 2001 Hazlett et al, 2005; Redcay and Courchesne, 2005; Schumann et al, 2010) . The cause of this increase in brain growth is unknown, but it appears to be largely symmetric, with increases in both gray matter and white matter (Hazlett et al, 2005; Schumann et al, 2010) . A small number of individuals with ASD do have macrocephaly in adulthood, which can be thought of as a separate biomarker (Courchesne et al, 1999) , but the majority do not, suggesting a decline in the rate of further brain growth in middle childhood (Courchesne et al, 2011 ). An increased rate of head growth early in life is also seen in some siblings of children with ASD who do not share the diagnosis, so this trait may also be an endophenotype for ASD (Constantino et al, 2010a; Elder et al, 2008) . Interestingly, Joe Piven's group identified an association between an SLC6A4 promoter polymorphism and cortical gray matter overgrowth in children with autism (Wassink et al, 2007) , potentially linking compromised 5-HT signaling during development to this well-recognized ASD biomarker.
Structural neuroimaging studies have also sought to identify biomarkers of autism. Regional findings have been inconsistent, but a few patterns may be emerging. First, there appears to be an initial increase in amygdala size in early childhood, followed by a possible decrease in size over time (Kim et al, 2010; Mosconi et al, 2009; Nacewicz et al, 2006; Schumann et al, 2009; Stanfield et al, 2008) . Second, there appears to be a general decrease in long-range connectivity (Barnea-Goraly et al, 2010; Frazier and Hardan, 2009; Shukla et al, 2010) . These findings are not perfectly consistent, but they have led to a hypothesis of increased local connectivity and decreased distant connectivity (Courchesne and Pierce, 2005) . Third, striatal size is increased in multiple studies, with size correlating positively with indices of repetitive behavior (Haznedar et al, 2006; Langen et al, 2007 Langen et al, , 2009 Sears et al, 1999) . Recent reviews of the structural neuroimaging literature highlight other findings that await consistent replication (Anagnostou and Taylor, 2011; Chen et al, 2011; Stanfield et al, 2008) . Ultimately, these structural findings may connect to postmortem neuropathological findings in autism, but sample sizes have been difficult to accrue and data are only just beginning to emerge, initial findings included decreased cortical minicolumn width (Casanova et al, 2002) and decreased GABA receptor binding (Fatemi et al, 2009; Oblak et al, 2011) in ASD subjects.
Functional neuroimaging studies in ASD present significant challenges. First, individuals with more severe impairments are unlikely to tolerate the scanner. Second, the inherent behavioral and cognitive differences in ASD may drive changes in brain response. For example, Richie Davidson's group used eye tracking to show that lower fusiform face area activation corresponded to ASD subjects not looking at the face stimulus while in the scanner (Dalton et al, 2005) . Similarly, tasks that probe cognitive deficits in ASD may show differences in brain activation that arise from the deficit itself, or reflect a compensation for the deficit. Basic sensory processing could also be altered in ASD (Foss-Feig et al, 2010; Kwakye et al, 2011; Marco et al, 2011) , resulting in abnormal response to almost any stimulus and without specificity for any particular task. Even with these caveats, quite a number of interesting functional neuroimaging findings have been reported that may relate to structural imaging finding, such as altered amgydala response to social stimuli (Kleinhans et al, 2009; Weng et al, 2011) . The interested reader is referred to several recent reviews on this topic (Anagnostou and Taylor, 2011; Di Martino et al, 2009) .
Additional peripheral biomarkers are beginning to emerge in ASD. For example, much interest has centered on possible mitochondrial dysfunction (Frye and Rossignol, 2011; Giulivi et al, 2010) . Although data are accumulating to support the existence of a subgroup of ASD children with such changes, the size of this subgroup and the specificity of these findings remain unclear (Oliveira et al, 2005) . Peripheral biomarkers related to the immune system have also generated considerable interest. Whereas evidence suggests that there may be altered immune system function in some children with ASD, the specific alterations appear to vary across studies and will require further analysis to reach consensus (Careaga et al, 2010) . Interestingly, SERT proteins are expressed by B-lymphocytes (Faraj et al, 1994; Meredith et al, 2005) and 5-HT signaling contributes to immune system function (Aune et al, 1994; Hofstetter et al, 2005; Young et al, 1993) .
GENETIC SYNDROMES THAT SHOW ASD FEATURES
Multiple genetic syndromes include ASD symptoms as part of a broader pattern of dysmorphology and medical morbidity. Space does not permit a review of all such syndromes, but here we highlight a few examples ( Table 2) that each have a substantial rate of ASD, include macrocephaly as a prominent feature, and affect signaling through the mTor pathway. A comprehensive review by Betancur (2011) provides extensive detail on many other genetic or genomic disorders that may lead to ASD susceptibility.
The most common, inherited cause of ASD is Fragile X syndrome (FraX), an X-linked recessive disorder that is found in 2-3% of individuals with ASD and is also the most common inherited cause of intellectual disability (Hagerman et al, 2009; Loesch et al, 2007 ). An expanding trinucleotide repeat in the 5 0 untranslated region of the FMR1 gene causes Fragile X in males (and in some females) with more than 200 copies of the repeat (Kremer et al, 1991) . Intellectual disability is a defining feature of FraX, along with a characteristic facial appearance, risk of seizures, and macroorchidism. Behavioral features frequently include hyperactivity, anxiety, sensory sensitivity, and avoidance of eye contact (Hagerman et al, 2009 ). Approximately 60% of individuals with FraX meet the criteria for ASD; although patterns of symptoms differ from the general ASD population (Hall et al, 2010; Harris et al, 2008) . As reviewed below and elsewhere (Bhogal and Jongens, 2010; Heulens and Kooy, 2011) , significant progress has been made in understanding the molecular changes that connect loss of FMR1 expression to the observed neurological, cognitive, and behavioral abnormalities in the mouse model. Prominent among the networks disturbed by loss of FMR1 is the mTor pathway and associated translational control mechanisms (Penagarikano et al, 2007; Sharma et al, 2010) .
Three additional single-gene disruption disorders cause excessive signaling through the mTor pathway and lead to increased risk of ASD, as reviewed below (Figure 2) . PTEN mutations lead to a hamartoma tumor syndrome as well as macrocephaly, and often ASD (Butler et al, 2005; Goffin et al, 2001) . Mice lacking PTEN expression in neurons show deficient sociability (Kwon et al, 2006; Zhou et al, 2009) , as do mice with hemizygous constitutive PTEN knockout (KO) (Page et al, 2009) . Interestingly, and with relevance to our subsequent section on potential 5-HT mechanisms in ASD, PTEN and SLC6A4 cooperatively exacerbate brain size and sociability phenotypes (Page et al, 2009 ). Tuberous sclerosis is caused by mutations in either hamartin (TSC1) or tuberin (TSC2) (Consortium, 1993; van Slegtenhorst et al, 1997) . Each of these syndromes, as well as related syndromes further upstream or downstream from mTor signaling (Table 1 and Figure 2 ), result in macrocephaly, a potential connection with this transient biomarker in ASD. As reviewed below, exciting research suggests that targeting control mechanisms for the mTor pathway may benefit individuals with these syndromes, and perhaps idiopathic ASD as well.
PATH FROM RARE GENETIC SYNDROMES TO NEW TREATMENTS IN ASD mTor and Regulation of Protein Synthesis
A major goal of preclinical studies of ASD susceptibility genes is the translation of disrupted signaling pathways to medications that can relieve physiological and behavioral deficits. In the past, such a challenge seemed naive, as lifelong alterations in cognitive function and social reciprocity were believed to derive from irreversible modifications of neuronal wiring established during early brain development. Initial findings suggest that, although the micro-circuitry of the brain in ASD subjects may be altered, deficits in synaptic signaling and plasticity may be of greater significance. The implications of this perspective are not insignificant as they raise the prospect that ASD traits could be ameliorated if the mechanisms compromised can be identified. Adding optimism to this idea, studies with transgenic mouse models of single-gene disorders that bear ASD features have demonstrated remarkable reductions, and in some cases elimination of behavioral deficits following either genetic and/or pharmacological manipulations (Ehninger et al, 2008a; Guy et al, 2007; Tropea et al, 2009; van Woerden et al, 2007; Zhou et al, 2009) . A comprehensive review of these findings has been published recently (Ehninger et al, 2008b ). As we do not cover them here, the interested reader should pay particular attention to mouse models of neurofibromatosis and Rett syndrome, where striking reversals of behavioral deficits have been achieved in mature animals (Ehninger et al, 2008a; Li et al, 2005) . Here, we outline other instances of such success to highlight the promise that basic research offers for the treatment of ASDs, with reference to pathways linked to mTOR and 5-HT signaling.
As noted above, tuberous sclerosis, derived from heterozygous inactivation of TSC1 or TSC2, presents with ASD features. The diagnostic features of this disorder are epithelial growths ('tubers') visible on MRI scans. However, studies fail to correlate the abundance of tubers with cognitive deficits in humans and in mouse models (Numis et al, 2011) . Most recently these deficits have been found to derive from neuronal signaling alterations associated with disrupted mTOR signaling. TSC1 and TSC2 form a heterodimeric complex that negatively regulates mTOR-signaling pathways that control protein translation. Protein synthesis within synaptic spines is a key feature of the long-term plasticity of neurons and is now known to be required for proper cognitive function, as well as the actions of chronically administered antidepressant medications (Li et al, 2010) . Ehninger et al reasoned that constitutively elevated mTOR signaling could be offset by rapamycin, an mTOR inhibitor. Remarkably, they achieved reversal of deficits in spatial learning and context discrimination with brief (5 day) postnatal administration of rapamycin (Ehninger et al, 2008a) . These studies nicely converge with studies involving manipulation of the lipid phosphatase PTEN, an upstream regulator of the TSC1/TSC2-mTOR pathway, which also can produce amelioration of the structural and neurological features of ASD in mouse models (Zhou et al, 2009) .
The paradigmatic disorder with ASD features that links to protein translation is FraX (Kremer et al, 1991) . The FMR1 protein (FMRP) binds to mRNAs and regulates their transport and translation (Ashley et al, 1993; Eberhart et al, 1996) . Huber et al (2002) first identified changes in long-term depression, a form of synaptic plasticity, in Fmr1-KO mice that is mediated by hyperactivity of metabotropic glutamate receptor type-5 (mGluR5) signaling and linked to the translation and trafficking of AMPA subtype glutamate receptors. These studies led Bear and colleagues (2004) to propose the 'mGluR theory' of FraX, positing that, in the absence of FMRP, mGluR1/5 stimulation results in excessive protein synthesis, thereby leading to excessive trafficking of AMPA receptors away from the cell surface. These investigators tested their hypothesis by decreasing the normal expression of mGluR5 (Dolen et al, 2007) , demonstrating a remarkable reversal of protein synthesis, dendritic spine alterations, and multiple behavioral phenotypes. These studies provide robust that manipulation of mGluR5-signaling pathways could provide relief for multiple aspects of FraX. They also provide a cogent example of how context can dramatically impact the penetrance of otherwise devastating genetic changes. Consistent with the ability of a partial loss of mGluR5 to reverse cognitive deficits of Fmr1-deficient mice, the mGluR1/5 antagonist MPEP reverses multiple behavioral abnormalities in Fmr1-null mice (de Vrij et al, 2008; Levenga et al, 2011; Yan et al, 2005) . Remarkably, Su et al (2011) recently reported that early, continuous, treatment with MPEP can even reverse dendritic spine abnormalities in Fmr1-KO mice. One preliminary clinical study of an mGluR5 antagonist in adult FraX subjects showed some promise, but only in the subgroup that had complete FMR1 methylation (Jacquemont et al, 2011) . Additional trials of mGluR5 antagonists in FraX are ongoing. The use of MPEP to treat features of ASDs may well extend beyond genetic disruptions in Fmr1. Thus, Jacki Crawley's group has observed that MPEP can reverse repetitive grooming behavior in the BTBR inbred strain of mice (Silverman et al, 2010) . Interestingly, loss of the Drosophila Fmr1 homolog leads to elevated dopamine and 5-HT synthesis (Zhang et al, 2005) . Gruss and Braun (2001) reported only modest correlates of these changes in monoamines in the Fmr1-null mouse; although we must remember that tissue levels provide a limited window on monoamine signaling in vivo. Further, the behavioral actions of 5-HT-elevating antidepressants have been linked to mTOR activation (Li et al, 2010) and alleles of 5HTTLPR have been found to associate with elevated aggression and destructive behavior in FraX patients . These findings suggest that features of altered 5-HT signaling, either with respect to early developmental signaling or enduring functional modulation, may derive in part from 5-HT signaling through the mTOR pathway. In this regard, Cleary et al (2008) found that the mTOR inhibitor rapamycin exerts activity typical of an SRI in animal models in suppressing struggling in both the forced-swim and tail suspension tests.
In summary, multiple single-gene disorders with ASD features derive from compromised regulation of mTORlinked signaling pathways. Whether deficits associated with idiopathic ASD derive from these pathways remains to be clarified. The heterogeneity of ASD should at the outset suggest that subgroups, behaviorally or molecularly defined, will likely need to be considered in therapeutic development. The search for synaptic signaling networks that control or are altered by mTOR signaling has revealed mGluR5 as a target whose manipulation can be projected to produce less side effects than targeting mTOR more directly. MPEP itself is likely a 'proof-of-concept' drug, most useful for preclinical animal studies. Additionally, only a limited number of behavioral features and synaptic alterations of ASD models have been queried for responsiveness to mGluR5 manipulation. With respect to the latter point, Suvrathan et al (2010) have recently extended the utility of MPEP for mGluR5 manipulation in reversing presynaptic deficits in the amygdala, work that could have relevance for changes in amygdala function in ASD. Finally, mGluR5 is likely but one 'druggable' target, including other surface receptors (eg, IL-1Rs), whose signaling can impact mTOR networks and thus be targeted for potential therapeutics. Interestingly, IL-1Rs have also emerged with respect to control of 5-HT signaling, as discussed below. We suspect that in the coming years, the study of this and other targets will contribute further momentum to an already active area of mTOR-targeted research.
FROM A BIOMARKER TO GENETIC VARIATION TO NEW TREATMENTS FOR ASD?
SERT-Mediated 5-HT Homeostasis
Based on the strong heritability of whole-blood 5-HT levels, Ed Cook and Carole Ober's labs mapped quantitative trait loci (QTLs) in a large founder population, revealing association with ITGB3, which encodes the SERT-associated protein integrin-b3 (Weiss et al, 2004) . A follow-up scan revealed association of both ITGB3 and SLC6A4 with wholeblood 5-HT specifically in males (Weiss et al, 2005) . Multiple linkage scans in ASD have shown significant evidence for linkage in the chromosome 17q region containing SLC6A4 (International Molecular Genetic Study of Autism Consortium, 2001; McCauley et al, 2004; Stone et al, 2004; Sutcliffe et al, 2005) . Sutcliffe et al (2005) showed that this linkage evidence is confined to families containing two or more affected males and no affected females, paralleling the QTL data for hyper-serotonemia noted above. As common SLC6A4 variants did not explain the strong linkage signal on 17q, the Sutcliffe and Blakely labs searched for rare variants (Sutcliffe et al, 2005) and identified multiple, rare non-synonymous variants, with each demonstrating increased 5-HT uptake . Interestingly, Dennis Murphy's group identified an SERT variant, Ile425Val, that segregates with obsessive-compulsive disorder (OCD) (as well as other neuropsychiatric disorders including Asperger's syndrome) in two unrelated pedigrees (Ozaki et al, 2003) . Gary Rudnick's group established that Ile425Val shows constitutively elevated 5-HT transport activity (Kilic et al, 2003) .
Targeting Altered 5-HT Signaling in ASD
Following a model of diminished synaptic 5-HT availability, one would predict that agents that reduce 5-HT availability would negatively impact ASD subjects, whereas SRIs should be beneficial. Consistent with this idea, short-term tryptophan depletion worsens ASD symptoms (McDougle et al, 1993) . Three small, randomized, placebo-controlled trials have found beneficial effects of the SRIs clomipramine, fluvoxamine, and fluoxetine for OCD-like behavior in ASD (Gordon et al, 1993; 
1996
). By contrast, one large, randomized trial reported no efficacy for the SRI citalopram for repetitive behavior in ASD subjects (King et al, 2009a) . Additional studies are needed that use selection criteria based on biomarkers, genotypes, or more specific impairing symptoms. The hyper-functional SERT variants were found in individuals with high scores on measures of rigid-compulsive traits and sensory aversion (Sutcliffe et al, 2005) , suggesting that SERT blockade might be most beneficial for these individuals. Despite the appeal of SRIs as available drugs, however, complete blockade of SERT is likely to overshoot a modulated restoration of 5-HT homeostasis (Table 3) . Below we discuss the network of gene products that regulate SERT where novel therapeutics could be developed that conditionally diminish SERT activity, permitting SERT to maintain a basal level of control over synaptic 5-HT. Prominent pathways that regulate SERT trafficking and catalytic function include those linked to PKC, PKG, and p38 MAPK signaling Steiner et al, 2009; Zhu et al, 2005) (Figure 3) . Importantly, many of the rare SERT coding variants show altered sensitivity to these signals . Certainly these networks, like mTOR pathways, are widespread and have many targets, making their therapeutic manipulation problematic. As with mTOR, however, there are ways to enter these pathways in a more cell-specific manner. For example, brain SERT activity can be enhanced by adenosine-A3 and Il-1b receptors (A3AR and IL-1R), with loss of regulation evident in A3AR and IL-1R-KO mice, respectively (Zhu et al, 2010 (Zhu et al, , 2007 . A3ARs signal to SERT through PKG and p38 MAPK, whereas IL-1Rs bypass PKG to activate p38 MAPK directly.
Given the capacity of A3AR and IL-1R activation to mimic the elevated 5-HT transport activity observed constitutively in ASD-associated SERT coding variants, it appears reasonable to consider whether pharmacological modulation of A3AR-or IL-1R-signaling pathways could lead to novel ASD therapeutics. Although a connection between IL-1Rs and 5-HT signaling is growing (Capuron and Miller, 2011; Zhu et al, 2011) , we focus our discussion here on A3ARs. Among the CNS adenosine receptor subtypes, A3ARs are the least studied, receiving more attention in the control of peripheral immune function and inflammation (Hasko et al, 2008) . Indeed, early investigators questioned whether A3ARs exist in the brain at all (Rivkees et al, 2000) . However, more recent efforts have established clear actions of A3AR agonists in protection of the CNS against hypoxia/ischemic and inflammatory insults (Borea et al, 2009; Haas and Selbach, 2000; Taliani et al, 2010) , as well as support for synaptic signaling and plasticity (Brand et al, 2001; Costenia et al, 2001; Dunwiddle et al, 1997; Macek et al, 1998) .
Recently, Zhu et al (2011) demonstrated that SERT and A3ARs colocalize in raphe neurons and can form an A3AR agonist-sensitive physical complex, providing further rationale to pursue pharmacological manipulation of A3AR-linked signaling for 5-HT-associated disorders. Trials of the A3AR-selective agonist CF 101 (IB-MECA) have been initiated and the agent has been found to be well-tolerated and capable of anti-inflammatory effects. Future studies will hopefully explore the action of this agent on behaviors supported by CNS 5-HT signaling. Additional proteins that coordinate A3AR signaling to SERT (Figure 3) should also be considered as potential therapeutic targets. SERTs exist in physical complexes with other signaling, scaffolding, and cytoskeletal proteins. Among these are NOS1 that produces nitric oxide to activate guanyl cyclase, producing cGMP and thereby activating the cGMP-responsive kinase PKG1a ( Quick, 2003; Steiner et al, 2009 ). Phosphodiesterases, such as PDE2, 5, and 9, hydrolyze cGMP, thereby reducing PKG stimulation of SERT. Agents that manipulate one or more of these steps in the A3AR-signaling pathway to SERT may provide novel approaches to normalize 5-HTassociated behavioral deficits. Paralleling efforts to model disruptions in mTor-regulatory pathways using mouse models, we have produced SERT Ala56-knock-in mice, introducing the most common of the hyper-functional ASD SERT variants into the native SERT gene locus (Veenstra-VanderWeele et al., unpublished data (submitted)). Importantly, SERT Ala56 mice show hyper-serotonemia and enhanced rates of 5-HT clearance in vivo, as predicted from findings of elevated 5-HT transport in vitro. As seen with the variant in transfected cells, mid-brain SERT Ala56 protein shows p38 MAPK-dependent hyper-phosphorylation, further linking physiological alterations to the SERT-regulatory network discussed above. SERT Ala56 mice show hypersensitivity at 5-HT1A and 5-HT2A receptors that likely arises as compensation for decreased synaptic 5-HT availability. Finally, we observe abnormalities in social, communication, and repetitive behavior in the SERT Ala56 mice, opening the door to detailed mechanistic studies in a model of autism with both face and construct validity. Studies are underway to understand the developmental vs dynamic effects of the SERT Ala56 variant in these animals, and to explore whether the physiological and behavioral alterations seen can be reversed. 5-HT1A-and 5-HT2A-based agents should be considered given the altered receptor sensitivities noted in the SERT Ala56 mice. Both receptors are currently targeted by pharmacologically complex agents such as risperidone (D 2 and 5-HT 2A/2C antagonist, etc.), which is effective for treatment of irritability in autism (McCracken et al, 2002; McPheeters et al, 2011) , and buspirone (5-HT 1A partial agonist; D 2 , a 1 , a 2 antagonist, etc.), which is under study in a large, randomized trial in autism (Edwards et al, 2006) .
SUMMARY
ASD is a heterogeneous and multi-factorial condition, and identifying subgroups of individuals will be necessary to gain traction into its pathophysiology and novel opportunities for treatment. Possible subgroups can be identified based on biomarkers, such as macrocephaly or indicators of mitochondrial dysfunction, or genetic findings, such as the neurexin-neuroligin system. Two of the established ASD subgroups are based on abnormal mTOR and 5-HT signaling in some individuals with ASD. These two networks represent opportunities to move from genetic and biomarker findings to model systems that allow studies of mechanisms and potential novel treatments for ASD. Multiple single-gene disorders with ASD features converge on altered control of mTOR signaling. Elegant work on the connection of mTOR signaling to glutamate-supported synaptic plasticity has led to considerations of regulatory glutamate receptors, particularly mGluR5, as a potential target for novel ASD medications. Hyper-serotonemia has now reached its 50th anniversary as a biomarker in ASD, compelling consideration of recent genetic studies that point to dysregulation of SERT and/or its regulatory networks. ASD-associated SERT coding variants provide a framework to better understand the contribution of altered 5-HT homeostasis to brain development and ASD-related behavior. We suggest future consideration of agents that engage proteins mediating SERT stimulation by A3ARs (eg, A3AR, NOS1, PKG1, p38 MAPK) but remind ourselves that, as with targeting mTOR pathways, the heterogeneity of ASD will likely require multiple approaches that are tailored to individuals with specific symptoms, genetics, and biomarker profiles. Figure 3 . Network of gene products regulating the expression, trafficking, and activity of the antidepressant-sensitive 5-HT transporters (SERT, SLC6A4). SERT controls the extracellular availability of 5-HT in the brain and periphery, and also recycles serotonin for further rounds of release. SERTmediated clearance of 5-HT limits the amplitude and duration of signaling of more than a dozen 5-HT receptors. We hypothesize that just as risk for ASD can derive from genetic variation in SERT that impacts 5-HT signaling during brain development, risk for ASD can also be generated through environmental or genetic perturbations of SERT-regulatory control mechanisms.
FUTURE RESEARCH DIRECTIONS
It is clear that new therapies are desperately needed for ASD. We believe that the soundest way forward is to follow the biology and decode its messages, whether they are established by genetics, the environment, or the continual dialog between the two. From single-gene disorders with ASD features comes a realization that the mTOR-signaling network may have many nodes where ASD risk is embedded. From biomarker, developmental, and genetic studies comes a reminder of how much, despite decades of study, we still have to learn about 5-HT, such as whether its signaling regulators might themselves represent one such node of the mTOR pathway and vice versa. Should this prove to be the case, agents that target specific 5-HT receptors and their signaling partners may prove beneficial in ASD treatment. As with mGluR5 and mTOR, the biology of 5-HT signaling can teach us how to target widespread signaling pathways in nuanced ways that can offer more help than harm. In that light, we suggest that targeting of SERT-regulatory pathways, as opposed to the pharmacological bludgeoning of the transporter itself, as with SRIs, may offer options for ASD treatments. Clearly, new animal models are needed, particularly those that result from environmental or genetic perturbations that lead to ASD traits in some individuals, as in the use of rare, penetrant coding mutations in genes expressed in brain areas impacted by the disorder, early in development. The era of trying to use animals with odd behaviors as models for neuropsychiatric disease is drawing to a close. Just because there is evidence of mitochondrial dysfunction or changes in the immune system, does not mean that we can accept any model that generates such changes. We can do better. Our models must be increasingly linked to the explicit mechanisms responsible for these changes, at least in some ASD subjects. Finally, we have noted above the intersections emerging between mTOR and 5-HT networks in the brain. There are observations outside the CNS that suggest similar convergences (eg, Soll et al, 2010) . The study of 5-HT has long captured the interest of translational researchers. The elucidation of translational mechanisms influenced by a convergence of 5-HT/mTOR-signaling pathways may further fuel this interest.
